Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $79.1252W HIGH $106.88
Volume
1.60 M
Value Traded
318.85 M
Short % Float
4.5%
-2.65%Week
-3.57%1 Month
-5.25%3 Month
-6.5%6 Month
-47.54%5 Year
+198.76%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
17.00 B
EPS (TTM)
4.23
P/E Ratio
21.08
Ent. Value
24.07 B
Total Shares
190.74 M
Float Shares
190.42 M
Insiders
0.17%
Institutions
106.64%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ZBH Catalyst Timeline
Dated clinical, regulatory and corporate events for Zimmer Biomet Holdings, Inc.
Past FDA Catalysts and PDUFA Decisions
How ZBH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D20 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 95%
Mid Cap(rank 627 of 660)
Percentile Rank
Zimmer Biomet Holdings, Inc. faces pipeline headwinds (20/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every ZBH program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Campbell Gary CraigOfficer (President, Americas) | Option | 2,368 2,368 held | $0.00 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ZBH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 2 % (-20 %) | 20.02 M | 232.56 K | -13.73% ( -37.00 K) |
ZBH Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ZBH ranks across every disease it competes in
Competitive Position is a premium feature
See how ZBH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialZBH News
ZBH▲ +0.3%today
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results
Zimmer Biomet Holdings, Inc. will host a webcast for its third quarter earnings on November 4, 2026, at 8:30 a.m. ET. A news release with the quarterly results will be available earlier that day at 6:30 a.m. ET. The conference call can be accessed via their Investor Relations website and will be available for replay.
Read more →ZBHZimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation
Zimmer Biomet has announced several leadership promotions aimed at enhancing its commercial strategy in the Americas. Effective October 1, Gary Campbell, Brian Hatcher, and Bradley Kessler will take on new roles to streamline operations and drive growth. The company remains optimistic about its financial outlook for 2026, emphasizing its commitment to innovation and market agility.
Read more →ZBHZimmer Biomet Announces Quarterly Dividend for Third Quarter of 2026
Zimmer Biomet Holdings, Inc. has announced a quarterly cash dividend of $0.24 per share for the third quarter of 2026. This dividend is set to be paid on or about October 30, 2026, to stockholders of record as of September 30, 2026. The announcement underscores the company's commitment to returning value to its shareholders.
Read more →ZBHZimmer Biomet Announces Second Quarter 2026 Financial Results
Zimmer Biomet reported strong financial results for the second quarter of 2026, with net sales reaching $2.177 billion, reflecting a 4.8% increase compared to the previous year. The company also saw a significant rise in diluted earnings per share, which increased by 33.8%. Additionally, Zimmer Biomet updated its full-year financial guidance upwards, indicating confidence in its growth trajectory. The company highlighted advancements in its product offerings, including FDA clearance for its ROSA® Shoulder System.
Read more →ZBHZimmer Biomet Names Chintan Desai President of Asia Pacific Region
Zimmer Biomet has appointed Chintan Desai as the new president of its Asia Pacific Region. Desai, who has extensive experience in the medical technology sector, previously held significant roles at Alcon and GE Healthcare. He replaces Sang Yi, who will leave the company at the end of August. This leadership change is anticipated to positively impact the company's strategy in the region.
Read more →ZBHZimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results
Zimmer Biomet Holdings, Inc. announced that it will host a webcast for its second quarter earnings conference call on August 5, 2026. The call will take place at 8:30 a.m. ET, with a news release detailing the financial results available earlier that day. Interested parties can access the webcast through the company's Investor Relations website.
Read more →ZBHZimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Zimmer Biomet Holdings, Inc. will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8. The management team will engage in a fireside chat at 10:40 a.m. ET, which will be accessible via a live audio webcast. This event highlights Zimmer Biomet's ongoing commitment to innovation in medical technology.
Read more →ZBHZimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026
Zimmer Biomet Holdings, Inc. has declared a quarterly cash dividend of $0.24 per share for the second quarter of 2026. This dividend will be payable on July 31, 2026, to stockholders of record by June 25, 2026. The announcement underscores the company's commitment to returning value to its shareholders.
Read more →ZBHZimmer Biomet Increases Share Repurchase Expectations
Zimmer Biomet Holdings, Inc. has raised its share repurchase expectations from $750 million to up to $1 billion for fiscal year 2026. This decision, which comes under a previously approved $1.5 billion share repurchase authorization, reflects the company's approach to managing its capital and reserves. The actual timing and amount of the repurchases will be contingent on various factors such as market conditions and stock prices. Zimmer Biomet continues to emphasize its commitment to innovation and maintaining a strong portfolio in medical technology.
Read more →ZBHZimmer Biomet Increases Share Repurchase Expectations -- Up to $1 Billion by Year End
Zimmer Biomet Holdings, Inc. has raised its share repurchase expectations to up to $1 billion for fiscal year 2026, an increase of $250 million from previous estimates. This decision is supported by the company's existing $1.5 billion share repurchase authorization. The actual timing and amount of repurchases will depend on market conditions and other financial considerations.
Read more →ZBHZimmer Biomet to Present at the BofA Securities 2026 Health Care Conference
Zimmer Biomet Holdings, Inc. will present at the Bank of America Securities Health Care Conference on May 13, 2026. The management team will participate in a fireside chat scheduled for 8:40 a.m. PT. A live audio webcast will be available on the company's Investor Relations website, with a replay option following the event.
Read more →ZBH▼ -10.6%on this news
Zimmer Biomet Announces Chief Financial Officer Transition Suketu Upadhyay to Depart; Paul Stellato Named Interim CFO
Zimmer Biomet Holdings, Inc. announced the departure of Chief Financial Officer Suketu Upadhyay, effective April 28, 2026. Paul Stellato has been named the interim CFO while the company searches for a permanent replacement. Stellato, who has over 20 years of finance experience, is expected to ensure continuity during this transition. The company remains focused on executing its strategy and delivering on its commitments despite this change in leadership.
Read more →ZBH▼ -10.6%on this news
Zimmer Biomet Announces First Quarter 2026 Financial Results
Zimmer Biomet Holdings, Inc. reported strong financial results for Q1 2026, with net sales of $2.087 billion, a 9.3% increase from the previous year. The company also saw a significant rise in diluted earnings per share, which reached $1.22, marking a 34.1% increase. Additionally, Zimmer Biomet updated its full-year financial guidance, reflecting confidence in its growth strategy and market performance. The company highlighted successful product launches and strategic initiatives contributing to its positive outlook.
Read more →ZBH▼ -10.6%on this news
Zimmer Biomet Announces Chief Financial Officer Transition
Zimmer Biomet announced the departure of Chief Financial Officer Suketu Upadhyay, effective April 28, 2026, for a new opportunity. Paul Stellato, the current Controller and Chief Accounting Officer, has been named interim CFO while the company searches for a permanent successor. The company expressed gratitude for Upadhyay's contributions and confidence in Stellato's leadership during this transition.
Read more →ZBHZimmer Biomet Announces Webcast and Conference Call of First Quarter 2026 Financial Results
Zimmer Biomet Holdings, Inc. has announced a webcast for its first quarter earnings conference call scheduled for April 28, 2026. The call will provide insights into the company's financial performance and will be accessible via their Investor Relations website. A news release with detailed results will precede the call.
Read more →ZBHZimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer
Zimmer Biomet has appointed Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer, effective April 14. Dr. Vigdorchik, an experienced orthopedic surgeon, will oversee the company's technology portfolio, including AI and robotics. His leadership is expected to accelerate innovation and strengthen clinical engagement within the organization.
Read more →ZBHZimmer Biomet Wins Three Awards at Healthcare Asia Medtech Awards 2026
Zimmer Biomet has been recognized with three awards at the Healthcare Asia Medtech Awards 2026 for its innovative contributions in orthopedic product development, digital health, and surgeon engagement. The company received accolades for its iodine-treated hip implant, the WalkAI recovery tracking platform, and its awareness campaign featuring Arnold Schwarzenegger. These awards highlight the company's commitment to improving patient outcomes across the Asia Pacific region.
Read more →ZBHZimmer Biomet to Release New Data, Highlight Key Innovations at American Academy of Orthopaedic Surgeons Annual Meeting
Zimmer Biomet will present new clinical data and innovations at the AAOS 2026 Annual Meeting. Arnold Schwarzenegger will serve as the Presidential Guest Speaker, discussing performance and teamwork. The company will showcase advanced orthopedic technologies, including robotics and AI-driven solutions, aimed at enhancing surgical precision and patient outcomes.
Read more →About Zimmer Biomet Holdings, Inc.
Headquarters345 EAST MAIN STREET, WARSAW, IN, 46580
BIOPHARMAWATCH ELITE PLUS
Trade the next ZBH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime